Pyxus International Reports 3.2% Sales Growth in Fiscal Year 2022

Aug.13.2022
Pyxus International Reports 3.2% Sales Growth in Fiscal Year 2022
Pyxus International reports 3.2% growth in sales and revenue for the fiscal year ending June 30, 2022.

Pyxus International is a tobacco company that operates globally.


Pyxus International has reported that its sales and other operating revenues for the fiscal year ending on June 30th, 2022 reached $343.9 million, representing a 3.2% increase from the same period in 2021. However, its net losses increased by 27.8%, amounting to $14.7 million, primarily due to a decrease in tax benefits by $7.6 million. Adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) increased by 17.1% to $17.3 million.


In a statement, Pyxus CEO Pieter Sikkel said, "As expected, our first quarter results were in line with the previous fiscal year. Demand from Asia increased and shipping times have become more normalized, but this was partially offset by longer shipping times from Africa and South America.


As of June 30th, 2022, our inventory has increased by $126 million compared to the previous year. This is primarily due to rising prices and processing costs for new crop green tobacco in South America, as well as the accelerated purchase activity for new crops in certain key markets. Additionally, over 90% our processed tobacco inventory is still allocated to specific customers.


The overall increase in inventory and the processing tobacco inventory levels we committed to have enabled us to meet current demand, and we anticipate strong shipment volumes for subsequent quarters in fiscal year 2023, consistent with historical trends. Despite higher green tobacco prices and processing costs in South America, we have effectively managed working capital to achieve our procurement objectives for the current crop cycle.


Due to unfavorable weather patterns from the La Niña season, crop yields in certain markets in Africa, Asia, and South America have fallen below expectations, exacerbating supply shortages. We are maintaining transparent dialogue with our clients regarding the impact of La Niña and inflation on our business. To address these and other market dynamics, we have accelerated purchasing activities in key markets and continue to invest in research trials, local projects, and additional training for our global agronomy team to further support our efforts to maximize grower efficiency and yields in unpredictable weather patterns.


We continue to anticipate that sales for the fiscal year 2023 will fall between $1.75 billion and $1.95 billion, while adjusted EBITDA will fall between $130 million and $160 million. Looking ahead, we are committed to restoring crop size and ensuring that the quantities in the upcoming years align with customers' expectations as we strive to provide value to stakeholders and work together towards a better world.


This article is compiled from third-party information and is intended for industry professionals to share and learn.


This article does not represent the views of 2FIRSTS and 2FIRSTS cannot confirm the truthfulness and accuracy of the article content. The translation of this article is solely for industry communication and research purposes.


Due to limitations in translation ability, the article may not express the original text accurately. Please refer to the original text for accuracy.


2FIRSTS aligns fully with the Chinese government on any domestic, Hong Kong, Macau, Taiwan, or foreign-related statements or positions.


Copyright of compiled information belongs to the original media and author. If there is any infringement, please contact us for deletion.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Reuters Exclusive: FDA’s Fast-Track Review of Nicotine Pouches Slows Over Youth and New-User Concerns
Reuters Exclusive: FDA’s Fast-Track Review of Nicotine Pouches Slows Over Youth and New-User Concerns
Reuters reported on April 1 that several popular nicotine pouch products still have not been cleared for sale in the United States despite a fast-track review pilot run by the U.S. Food and Drug Administration. Three sources said FDA reviewers have taken a cautious approach because of potential risks to youth and other non-tobacco users, including the possibility of driving nicotine addiction among adults who do not already smoke.
Apr.02 by 2FIRSTS.ai
UK’s North Yorkshire Council plans up to £477,000 spend on e-cigarettes to support quitting smoking
UK’s North Yorkshire Council plans up to £477,000 spend on e-cigarettes to support quitting smoking
North Yorkshire Council in the UK is set to spend up to £477,000 on e-cigarettes to support residents quitting smoking. Since e-cigarettes were added to the council’s Living Well Smokefree service in July 2023, 487 people have used them to quit, with about a third remaining smoke-free after a year.
Mar.03 by 2FIRSTS.ai
Research Summary | NHANES Study: Smoking or E-Cigarette Use Linked to Higher Prevalence of Elevated Blood Pressure and Hypertension
Research Summary | NHANES Study: Smoking or E-Cigarette Use Linked to Higher Prevalence of Elevated Blood Pressure and Hypertension
A cross-sectional analysis based on the US NHANES 2021–2023 cycle, including 6,262 participants aged over 12, found that compared with people who neither smoke nor vape, those who smoke and/or use e-cigarettes had a higher prevalence of elevated blood pressure and hypertension. After full adjustment, smoking/vaping was associated with elevated blood pressure (aOR 1.34) and hypertension (aOR 1.46), and with a 1.05 mmHg higher diastolic blood pressure.
Feb.09 by 2FIRSTS.ai
Special Report | PLONQ Expands in China With New Shenzhen Hub to Accelerate R&D and Partnerships
Special Report | PLONQ Expands in China With New Shenzhen Hub to Accelerate R&D and Partnerships
On March 27, 2026, PLONQ officially opened its upgraded Shenzhen office, reinforcing its long-term commitment to China and marking a new phase of growth. As a leading vape brand in Russia, PLONQ is expanding into new product categories while strengthening R&D, engineering collaboration, and partnerships with Chinese companies. The Shenzhen office will accelerate product development, enhance cooperation with technology and manufacturing partners, and support future growth initiatives.
Apr.01
FDA Filing Shows RIF Notices for 229 CTP Employees Were Largely Rescinded
FDA Filing Shows RIF Notices for 229 CTP Employees Were Largely Rescinded
A court declaration signed by FDA official Melanie M. Keller on March 24, 2026 detailed the status of previously issued reduction-in-force notices affecting employees at the Center for Tobacco Products (CTP).
Apr.01 by 2FIRSTS.ai
Philip Morris Limited Launches Delia to Expand IQOS Iluma Consumables Portfolio
Philip Morris Limited Launches Delia to Expand IQOS Iluma Consumables Portfolio
Philip Morris Limited has announced the launch of Delia, the latest addition to its portfolio of heated tobacco and zero-tobacco sticks exclusively compatible with the IQOS Iluma range.
Apr.03 by 2FIRSTS.ai